Clinical trials: COPD Exacerbations
COPD Exacerbation
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized…
- Trial name
- NCT04655170
- Testing
- Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Graduate School of Medicine
COPD Exacerbation
Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Study 2)
This study is being done to test the comparative effectiveness of participating in a Pulmonary Rehabilitation Program at home using new technology and health coaching following dismissal from the hospital compared to the referral…
- Trial name
- NCT04521608
- Testing
- Intervention- Home-based Pulmonary Rehabilitation
- Where
- 2 sites in United States
- Volunteers
- 296 people
- Sponsor
- Mayo Clinic
COPD, COPD Exacerbation Acute
ProAir Digihaler in COPD Disease Management: A Real World Study
A pilot study to explore the utilization of the TEVA ProAir Digihaler rescue medication use and inhalation parameters to identify disease deterioration to help in the management of COPD patients in clinical practice.
- Trial name
- NCT04821869
- Testing
- ProAir Digihaler, Digihaler
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pulmonary Research Institute of Southeast Michigan
COPD Exacerbation
Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
Determination of specific molecular breath patterns by secondary electrospray ionization mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation.
- Trial name
- TripleEX (NCT04638920)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 35 people
- Sponsor
- Malcolm Kohler
COPD Exacerbation
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD
The primary objective of the study is to determine the percentage of patients with "therapeutic success" at the end of the cycle of antibiotic therapy (10 days), in the two treatment groups (levofloxacin and prulifloxacin).
- Trial name
- FLOR (NCT01710488)
- Testing
- Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day
- Where
- 25 sites in Italy
- Volunteers
- 258 people
- Sponsor
- Fadoi Foundation, Italy
COPD, COPD Exacerbation
Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, and over 90% of COPD-related deaths occurring in low- and middle-income countries (LMICs).
- Conditions
- COPD, COPD Exacerbation, COPD Exacerbation Acute, Pollution Related Respiratory Disorder
- Trial name
- NCT03984188
- Testing
- Theophylline ER, Standard of Care Treatment
- Where
- 2 sites in Uganda
- Volunteers
- 100 people
- Sponsor
- University of Miami
Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
Effect of Blood Flow Restriction Resistance Exercises in COPDAE In-patient Rehabilitation
This is a randomised controlled trial of the blood flow restriction resistance exercise (BFR-RE) for early rehabilitation of chronic obstructive pulmonary disease acute exacerbation (COPDAE) in the Haven of Hope Hospital.
- Trial name
- NCT04448236
- Testing
- Blood flow restriction resistance exercise
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- Hospital Authority, Hong Kong
COPD Exacerbation Acute
Treatment of Pneumocystis in COPD (the TOPIC Study)
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease associated with chronic inflammation in the airways and lung, resulting in significant morbidity and mortality worldwide.
- Trial name
- NCT05418777
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Corewell Health East
COPD Exacerbation
Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third-leading cause of…
- Trial name
- COPD-ST2OP (NCT03615040)
- Testing
- MSTT1041A
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- University of Leicester
COPD Exacerbation
Telehealth Pulmonary Rehabilitation for Hispanic and African-American Patients Admitted With Exacerbation of COPD
Chronic Obstructive Pulmonary Disease (COPD), also known as emphysema, is the leading cause of hospitalization for older adults in the U.S., and a leading cause of death.
- Trial name
- NCT03007485
- Testing
- Telehealth Pulmonary Rehabilitation
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Northwell Health
COPD, COPD Exacerbation
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
This will be a non-blinded feasibility (pilot) study comparing triple therapy nebulizer vs dry powdered inhalers (DPI) for care transitions in Chronic obstructive pulmonary disease (COPD) exacerbation patients.
- Trial name
- NCT03219866
- Testing
- Nebulizers, Dry Powder Inhaler, Brovana
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
COPD Exacerbation
Early Assisted Discharge for COPD Exacerbations With Telemonitoring.
To determine if an early assisted discharge program for acute exacerbations of COPD (AECOPD), with telemonitoring and telephone control, is equally effective and more efficient in terms of use of health care resources, that a…
- Trial name
- NCT01951261
- Testing
- Telemonitoring and telephone control
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Dr. López Viña
COPD Exacerbation
Acupuncture Treatment of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Chronic obstructive pulmonary disease (COPD) is a major health problem. Acute exacerbations are a health-care burden involving frequent hospitalizations and elevated costs.
- Trial name
- NCT03398213
- Testing
- Acupuncture
- Where
- 2 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Bnai Zion Medical Center
COPD Exacerbation
Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Pilot Study)
This pilot study will look at investigating barriers, facilitators, adherence and effectiveness of an interactive home-based pulmonary rehabilitation program and health coaching for patients who have recently been hospitalized…
- Trial name
- NCT03865329
- Testing
- Intervention- Home-based Pulmonary Rehabilitation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
COPD Exacerbation
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD.
- Trial name
- NCT02291016
- Testing
- Formoterol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
COPD Exacerbation
TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics…
- Trial name
- NCT00789997
- Testing
- Prednisone, Etanercept, levofloxacin
- Volunteers
- 81 people
- Sponsor
- Ottawa Hospital Research Institute